Fujifilm Diosynth Biotechnologies Reserves Capacity for COVID-19 Therapeutics Accelerator
Fujifilm allocates production volumes for COVID-19 treatments in 2021 at its Denmark facility.
CDMO Fujifilm Diosynth Biotechnologies announced in an April 30, 2020 press release that it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator. The Therapeutics Accelerator is an initiative launched by the Bill and Melinda Gates Foundation, Wellcome, and Mastercard in response to the global pandemic. The Therapeutics Accelerator is working to accelerate drug development and will identify a promising COVID-19 therapeutic candidate based on efficacy and safety data demonstrated in clinical trials.
Fujifilm Diosynth Biotechnologies will reserve production volumes for 2021 at its large-scale biologics production facility in Hillerød, Denmark. The company will work with a selected pharmaceutical partner in supporting manufacture and dedicated supply for patients with COVID-19 in lower-income countries.
The company’s Hillerød cGMP facility is equipped with six, 20,000-L bioreactors for the manufacture of cell-culture derived biologics for clinical and commercial use. The agreement also anticipates that the company will support drug product and assembly, label, and packaging requirements.
Source: FujiFilm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
